Highlights
- 1Nature communications · 2023
- 2Angewandte Chemie (International ed. in English) · 2021
- 3Cell chemical biology · 2023
Publications
51 publications
Funding
17 grantsView NIH portfolio on RePORTER ↗
Active
6 grants- PIR01AI143714-08Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarialsNational Institute of Allergy and Infectious Diseases · 2019–2029· 2 renewals
- PIHT9425-26-1-E178Pharmacological Targeting of UBR5 for Breast Cancer ImmunotherapyU.S. Department of Defense · 2026–2029
- PIR01CA276053-03Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancerNational Cancer Institute · 2024–2028
- PIR01AI177635-04Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistanceNational Institute of Allergy and Infectious Diseases · 2023–2028· 2 renewals
- Co-IR21AI185437-01A1Targeted Degradation of Mycobacterial PknG for Host Control of TuberculosisNational Institute of Allergy and Infectious Diseases · 2025–2027
- PIIBI 227875-01IpiNovyx CollaborationIpiNovyx Bio, Inc. · 2022–2026BioPharma Alliance
Completed grants (11)
- Sub-PIW81XWH-22-1-0521Targeting the Plasmodium proteasome for prophylaxis and treatment of drug-resistant malaria in US Military personnelU.S. Department of Defense · 2022–2024 · via The Board of Trustees of the Leland Stanford Junior University
- Co-IBF 190027-01Investigating the proteasome of the malaria parasite Plasmodium falciparumThe Brockman Foundation · 2019–2024
- PIR21AI153485-02Compounds that force Plasmodium falciparum to produce its own inhibitorsNational Institute of Allergy and Infectious Diseases · 2020–2023
- PIR21AI144552-02Macrocyclic proteasome inhibitors for treatment of tuberculosisNational Institute of Allergy and Infectious Diseases · 2020–2023
- Sub-PIR01AI134842-05The Novel Role of the Immunoproteasome Subunit LMP7 in Allo-Immunity and T Cell ExhaustionNational Institute of Allergy and Infectious Diseases · 2017–2022 · via The Brigham & Women's Hospital INC
- PIDFI 180181-02Conversion of Novel and Orally Bioavailable Pathogens Proteasome Inhibitors to Human Proteasome InhibitorsDaedalus Fund for Innovation (Weill Cornell) · 2017–2021BioPharma Alliance
- Co-IDF 180106-1In Search of an Inhibitor of the E3 Ubiquitin Ligase UBR5 for Cancer TherapyDaedalus Fund for Innovation (Weill Cornell) · 2017–2020
- PIR21AI123794-02Novel Inhibitors of Malaria ProteasomeNational Institute of Allergy and Infectious Diseases · 2017–2020
- KPBAA 183322-01ABLS IV LLC Research Collaboration AgreementAllied-Bristol Life Sciences · 2017–2019Contract
- KPR01AI064768-07Biology of Lipoamide Dehydrogenase and 2-hydroxy-3-oxoadipate Synthase in MtbNational Institute of Allergy and Infectious Diseases · 2010–2017
- PIR21AI101393-02EWOSpecies Selective Dipeptide Inhibitors for Mtb ProteasomeNational Institute of Allergy and Infectious Diseases · 2013–2015
Available technologies
1 technologyView full WCM portfolio ↗
News mentions
2 mentionsView all WCM news ↗
- $2.5 Million Department of Defense Grant Funds Development of Targeted Therapy for Triple-Negative Breast CancerJuly 16, 2026
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
- Structural Study Points the Way to Better Malaria DrugsJanuary 18, 2024
Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
Media highlights
1 clip
- Department Of Defense Grant Funds Development of Targeted Therapy For Triple-Negative Breast CancerOncology Times · September 1, 2026
Mentoring
3 mentees
External relationships
Ownership
IpiNovyx Bio, Inc.
Proprietary Interest
IpiNovyx Bio, Inc.
Other
IpiNovyx Bio, Inc.